1
|
Díaz-Balzac CA, Pillinger D, Wittlin SD. Continuous subcutaneous insulin infusions: Closing the loop. J Clin Endocrinol Metab 2022; 108:1019-1033. [PMID: 36573281 DOI: 10.1210/clinem/dgac746] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Indexed: 12/29/2022]
Abstract
CONTEXT Continuous subcutaneous insulin infusions (CSIIs) and continuous glucose monitors (CGMs) have revolutionized the management of diabetes mellitus (DM). Over the last two decades the development of advanced, small, and user-friendly technology has progressed substantially, essentially closing the loop in the fasting and post-absorptive state, nearing the promise of an artificial pancreas. The momentum was mostly driven by the diabetes community itself, to improve its health and quality of life. EVIDENCE ACQUISITION Literature regarding CSII and CGM was reviewed. EVIDENCE SYNTHESIS Management of DM aims to regulate blood glucose to prevent long term micro and macrovascular complications. CSIIs combined with CGMs provide an integrated system to maintain tight glycemic control in a safe and uninterrupted fashion, while minimizing hypoglycemic events. Recent advances have allowed to 'close the loop' by better mimicking endogenous insulin secretion and glucose level regulation. Evidence supports sustained improvement in glycemic control with reduced episodes of hypoglycemia using these systems, while improving quality of life. Ongoing work in delivery algorithms with or without counterregulatory hormones will allow for further layers of regulation of the artificial pancreas. CONCLUSION Ongoing efforts to develop an artificial pancreas have created effective tools to improve the management of DM. CSIIs and CGMs are useful in diverse populations ranging from children to the elderly, as well as in various clinical contexts. Individually and more so together, these have had a tremendous impact in the management of DM, while avoiding treatment fatigue. However, cost and accessibility are still a hindrance to its wider application.
Collapse
Affiliation(s)
- Carlos A Díaz-Balzac
- Division of Endocrinology, Diabetes and Metabolism, University of Rochester Medical Center, 601 Elmwood Avenue, Box 693, Rochester, NY 14642, USA
| | - David Pillinger
- Division of Endocrinology, Diabetes and Metabolism, University of Rochester Medical Center, 601 Elmwood Avenue, Box 693, Rochester, NY 14642, USA
| | - Steven D Wittlin
- Division of Endocrinology, Diabetes and Metabolism, University of Rochester Medical Center, 601 Elmwood Avenue, Box 693, Rochester, NY 14642, USA
| |
Collapse
|
2
|
de Farias JLCB, Bessa WM. Intelligent Control with Artificial Neural Networks for Automated Insulin Delivery Systems. Bioengineering (Basel) 2022; 9:664. [PMID: 36354574 PMCID: PMC9687429 DOI: 10.3390/bioengineering9110664] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2023] Open
Abstract
Type 1 diabetes mellitus is a disease that affects millions of people around the world. Recent progress in embedded devices has allowed the development of artificial pancreas that can pump insulin subcutaneously to automatically regulate blood glucose levels in diabetic patients. In this work, a Lyapunov-based intelligent controller using artificial neural networks is proposed for application in automated insulin delivery systems. The adoption of an adaptive radial basis function network within the control scheme allows regulation of blood glucose levels without the need for a dynamic model of the system. The proposed model-free approach does not require the patient to inform when they are going to have a meal and is able to deal with inter- and intrapatient variability. To ensure safe operating conditions, the stability of the control law is rigorously addressed through a Lyapunov-like analysis. In silico analysis using virtual patients are provided to demonstrate the effectiveness of the proposed control scheme, showing its ability to maintain normoglycemia in patients with type 1 diabetes mellitus. Three different scenarios were considered: one long- and two short-term simulation studies. In the short-term analyses, 20 virtual patients were simulated for a period of 7 days, with and without prior basal therapy, while in the long-term simulation, 1 virtual patient was assessed over 63 days. The results show that the proposed approach was able to guarantee a time in the range above 95% for the target glycemia in all scenarios studied, which is in fact well above the desirable 70%. Even in the long-term analysis, the intelligent control scheme was able to keep blood glucose metrics within clinical care standards: mean blood glucose of 119.59 mg/dL with standard deviation of 32.02 mg/dL and coefficient of variation of 26.78%, all below the respective reference values.
Collapse
|
3
|
Acharya D, Das DK. Extended Kalman filter state estimation–based nonlinear explicit model predictive control design for blood glucose regulation of type 1 diabetic patient. Med Biol Eng Comput 2022; 60:1347-1361. [DOI: 10.1007/s11517-022-02511-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 01/18/2022] [Indexed: 10/18/2022]
|
4
|
Acharya D, Das DK. An efficient nonlinear explicit model predictive control to regulate blood glucose in type-1 diabetic patient under parametric uncertainties. Biomed Signal Process Control 2022. [DOI: 10.1016/j.bspc.2021.103166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
5
|
Intelligent automated drug administration and therapy: future of healthcare. Drug Deliv Transl Res 2021; 11:1878-1902. [PMID: 33447941 DOI: 10.1007/s13346-020-00876-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2020] [Indexed: 12/13/2022]
Abstract
In the twenty-first century, the collaboration of control engineering and the healthcare sector has matured to some extent; however, the future will have promising opportunities, vast applications, and some challenges. Due to advancements in processing speed, the closed-loop administration of drugs has gained popularity for critically ill patients in intensive care units and routine life such as personalized drug delivery or implantable therapeutic devices. For developing a closed-loop drug delivery system, the control system works with a group of technologies like sensors, micromachining, wireless technologies, and pharmaceuticals. Recently, the integration of artificial intelligence techniques such as fuzzy logic, neural network, and reinforcement learning with the closed-loop drug delivery systems has brought their applications closer to fully intelligent automatic healthcare systems. This review's main objectives are to discuss the current developments, possibilities, and future visions in closed-loop drug delivery systems, for providing treatment to patients suffering from chronic diseases. It summarizes the present insight of closed-loop drug delivery/therapy for diabetes, gastrointestinal tract disease, cancer, anesthesia administration, cardiac ailments, and neurological disorders, from a perspective to show the research in the area of control theory.
Collapse
|
6
|
Garcia-Tirado J, Corbett JP, Boiroux D, Jørgensen JB, Breton MD. Closed-Loop Control with Unannounced Exercise for Adults with Type 1 Diabetes using the Ensemble Model Predictive Control. JOURNAL OF PROCESS CONTROL 2019; 80:202-210. [PMID: 32831483 PMCID: PMC7437946 DOI: 10.1016/j.jprocont.2019.05.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
This paper presents an individualized Ensemble Model Predictive Control (EnMPC) algorithm for blood glucose (BG) stabilization and hypoglycemia prevention in people with type 1 diabetes (T1D) who exercise regularly. The EnMPC formulation can be regarded as a simplified multi-stage MPC allowing for the consideration of N en scenarios gathered from the patient's recent behavior. The patient's physical activity behavior is characterized by an exercise-specific input signal derived from the deconvolution of the patient's continuous glucose monitor (CGM), accounting for known inputs such as meal, and insulin pump records. The EnMPC controller was tested in a cohort of in silico patients with representative inter-subject and intra-subject variability from the FDA-accepted UVA/Padova simulation platform. Results show a significant improvement on hypoglycemia prevention after 30 min of mild to moderate exercise in comparison to a similarly tuned baseline controller (rMPC); with a reduction in hypoglycemia occurrences (< 70 mg/dL), from 3.08% ± 3.55 with rMPC to 0.78% ± 2.04 with EnMPC (P < 0.05).
Collapse
Affiliation(s)
- Jose Garcia-Tirado
- Center for Diabetes Technology, University of Virginia, Charlottesville, VA
| | - John P. Corbett
- Center for Diabetes Technology, University of Virginia, Charlottesville, VA
- Department of Systems and Information Engineering, University of Virginia, Charlottesville, VA
| | - Dimitri Boiroux
- Department of Applied Mathematics and Computer Science, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark
- Danish Diabetes Academy, DK-5000 Odense, Denmark
| | - John Bagterp Jørgensen
- Department of Applied Mathematics and Computer Science, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark
| | - Marc D Breton
- Center for Diabetes Technology, University of Virginia, Charlottesville, VA
| |
Collapse
|
7
|
Abstract
Over the past 50 years, the diabetes technology field progressed remarkably through self-monitoring of blood glucose (SMBG), continuous subcutaneous insulin infusion (CSII), risk and variability analysis, mathematical models and computer simulation of the human metabolic system, real-time continuous glucose monitoring (CGM), and control algorithms driving closed-loop control systems known as the "artificial pancreas" (AP). This review follows these developments, beginning with an overview of the functioning of the human metabolic system in health and in diabetes and of its detailed quantitative network modeling. The review continues with a brief account of the first AP studies that used intravenous glucose monitoring and insulin infusion, and with notes about CSII and CGM-the technologies that made possible the development of contemporary AP systems. In conclusion, engineering lessons learned from AP research, and the clinical need for AP systems to prove their safety and efficacy in large-scale clinical trials, are outlined.
Collapse
Affiliation(s)
- Boris Kovatchev
- Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia 22908
| |
Collapse
|
8
|
Shirin A, Della Rossa F, Klickstein I, Russell J, Sorrentino F. Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon. PLoS One 2019; 14:e0213665. [PMID: 30893335 PMCID: PMC6426249 DOI: 10.1371/journal.pone.0213665] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 02/26/2019] [Indexed: 12/11/2022] Open
Abstract
The Glucose-Insulin-Glucagon nonlinear model accurately describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes. Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and glucagon (dual therapy) that can optimally maintain the blood glucose level within desired limits after consumption of a meal and prevent the onset of both hypoglycemia and hyperglycemia. This problem is formulated as a nonlinear optimal control problem, which we solve using the numerical optimal control package PSOPT. Interestingly, in the case of monotherapy, we find the optimal solution is close to the standard method of insulin based glucose regulation, which is to assume a variable amount of insulin half an hour before each meal. We also find that the optimal dual therapy (that uses both insulin and glucagon) is better able to regulate glucose as compared to using insulin alone. We also propose an ad-hoc rule for both the dosage and the time of delivery of insulin and glucagon.
Collapse
Affiliation(s)
- Afroza Shirin
- Mechanical Engineering Department, University of New Mexico, Albuquerque, NM 87131, United States of America
- * E-mail:
| | - Fabio Della Rossa
- Mechanical Engineering Department, University of New Mexico, Albuquerque, NM 87131, United States of America
| | - Isaac Klickstein
- Mechanical Engineering Department, University of New Mexico, Albuquerque, NM 87131, United States of America
| | - John Russell
- Mechanical Engineering Department, University of New Mexico, Albuquerque, NM 87131, United States of America
| | - Francesco Sorrentino
- Mechanical Engineering Department, University of New Mexico, Albuquerque, NM 87131, United States of America
| |
Collapse
|
9
|
Kovatchev B. Automated closed-loop control of diabetes: the artificial pancreas. Bioelectron Med 2018; 4:14. [PMID: 32232090 PMCID: PMC7098217 DOI: 10.1186/s42234-018-0015-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Accepted: 10/08/2018] [Indexed: 12/28/2022] Open
Abstract
The incidence of Diabetes Mellitus is on the rise worldwide, which exerts enormous health toll on the population and enormous pressure on the healthcare systems. Now, almost hundred years after the discovery of insulin in 1921, the optimization problem of diabetes is well formulated as maintenance of strict glycemic control without increasing the risk for hypoglycemia. External insulin administration is mandatory for people with type 1 diabetes; various medications, as well as basal and prandial insulin, are included in the daily treatment of type 2 diabetes. This review follows the development of the Diabetes Technology field which, since the 1970s, progressed remarkably through continuous subcutaneous insulin infusion (CSII), mathematical models and computer simulation of the human metabolic system, real-time continuous glucose monitoring (CGM), and control algorithms driving closed-loop control systems known as the "artificial pancreas" (AP). All of these developments included significant engineering advances and substantial bioelectronics progress in the sensing of blood glucose levels, insulin delivery, and control design. The key technologies that enabled contemporary AP systems are CSII and CGM, both of which became available and sufficiently portable in the beginning of this century. This powered the quest for wearable home-use AP, which is now under way with prototypes tested in outpatient studies during the past 6 years. Pivotal trials of new AP technologies are ongoing, and the first hybrid closed-loop system has been approved by the FDA for clinical use. Thus, the closed-loop AP is well on its way to become the digital-age treatment of diabetes.
Collapse
Affiliation(s)
- Boris Kovatchev
- Center for Diabetes Technology, University of Virginia, P.O. Box 400888, Charlottesville, VA 22908 USA
| |
Collapse
|
10
|
Garcia-Tirado J, Zuluaga-Bedoya C, Breton MD. Identifiability Analysis of Three Control-Oriented Models for Use in Artificial Pancreas Systems. J Diabetes Sci Technol 2018; 12:937-952. [PMID: 30095007 PMCID: PMC6134618 DOI: 10.1177/1932296818788873] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Our aim is to analyze the identifiability of three commonly used control-oriented models for glucose control in patients with type 1 diabetes (T1D). METHODS Structural and practical identifiability analysis were performed on three published control-oriented models for glucose control in patients with type 1 diabetes (T1D): the subcutaneous oral glucose minimal model (SOGMM), the intensive control insulin-nutrition-glucose (ICING) model, and the minimal model control-oriented (MMC). Structural identifiability was addressed with a combination of the generating series (GS) approach and identifiability tableaus whereas practical identifiability was studied by means of (1) global ranking of parameters via sensitivity analysis together with the Latin hypercube sampling method (LHS) and (2) collinearity analysis among parameters. For practical identifiability and model identification, continuous glucose monitor (CGM), insulin pump, and meal records were selected from a set of patients (n = 5) on continuous subcutaneous insulin infusion (CSII) that underwent a clinical trial in an outpatient setting. The performance of the identified models was analyzed by means of the root mean square (RMS) criterion. RESULTS A reliable set of identifiable parameters was found for every studied model after analyzing the possible identifiability issues of the original parameter sets. According to an importance factor ([Formula: see text]), it was shown that insulin sensitivity is not the most influential parameter from the dynamical point of view, that is, is not the parameter impacting the outputs the most of the three models, contrary to what is assumed in the literature. For the test data, the models demonstrated similar performance with most RMS values around 20 mg/dl (min: 15.64 mg/dl, max: 51.32 mg/dl). However, MMC failed to identify the model for patient 4. Also, considering the three models, the MMC model showed the higher parameter variability when reidentified every 6 hours. CONCLUSION This study shows that both structural and practical identifiability analysis need to be considered prior to the model identification/individualization in patients with T1D. It was shown that all the studied models are able to represent the CGM data, yet their usefulness in a hypothetical artificial pancreas could be a matter of debate. In spite that the three models do not capture all the dynamics and metabolic effects as a maximal model (ie, our FDA-accepted UVa/Padova simulator), SOGMM and ICING appear to be more appealing than MMC regarding both the performance and parameter variability after reidentification. Although the model predictions of ICING are comparable to the ones of the SOGMM model, the large parameter set makes the model prone to overfitting if all parameters are identified. Moreover, the existence of a high nonlinear function like [Formula: see text] prevents the use of tools from the linear systems theory.
Collapse
Affiliation(s)
- Jose Garcia-Tirado
- Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA
| | - Christian Zuluaga-Bedoya
- Dynamic Processes Research Group KALMAN, Universidad Nacional de Colombia, Medellín, Antioquia, Colombia
| | - Marc D. Breton
- Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA
| |
Collapse
|
11
|
Scholten K, Meng E. A review of implantable biosensors for closed-loop glucose control and other drug delivery applications. Int J Pharm 2018; 544:319-334. [DOI: 10.1016/j.ijpharm.2018.02.022] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 01/30/2018] [Accepted: 02/15/2018] [Indexed: 12/19/2022]
|
12
|
Guilhem I, Penet M, Paillard A, Carpentier M, Esvant A, Lefebvre MA, Poirier JY. Manual Closed-Loop Insulin Delivery Using a Saddle Point Model Predictive Control Algorithm: Results of a Crossover Randomized Overnight Study. J Diabetes Sci Technol 2017; 11:1007-1014. [PMID: 28677416 PMCID: PMC5951001 DOI: 10.1177/1932296817717503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND The purpose was to assess the efficacy of a new closed-loop algorithm (Saddle Point Model Predictive Control, SP-MPC) in achieving nocturnal normoglycemia while reducing the risk of hypoglycemia in patients with type 1 diabetes. METHOD In this randomized crossover study, 10 adult patients (mean hemoglobin A1c 7.35 ± 1.04%) were assigned to be treated overnight by open loop using sensor-augmented pump therapy (open-loop SAP) or manual closed-loop delivery. During closed loop, insulin doses were calculated using the SP-MPC algorithm and administered as manual boluses every 15 minutes from 9:00 pm to 8:00 am. Patients consumed a self-selected meal (65-125 g of carbohydrates) at 7:00 pm accompanied by their usual prandial bolus. Blood glucose was measured every 30 minutes. The primary endpoints were the time spent in target (70-145 mg/dl) and time spent below 70 mg/dl from 11:00 pm to 8:00 am. RESULTS Time spent in target did not differ between closed-loop and open-loop SAP. The number of hypoglycemic events (<70 mg/dl) was reduced 2.8-fold in closed loop (n = 5, median = 0/patient/hour; interquartile range: 0-0.11) as compared to open-loop SAP (n = 14, median = 0.22/patient/hour, 0.02-0.22) ( P = .02). The area under the curve for sensor glucose values >145 mg/dl was significantly lower during closed-loop than during open-loop SAP ( P = .03) as well as HBGI ( P = .02). CONCLUSIONS This pilot study suggests that the use of the SP-MPC algorithm may improve mean overnight glucose control and reduce the number of hypoglycemic events as compared to SAP therapy.
Collapse
Affiliation(s)
- Isabelle Guilhem
- CHU de Rennes, Department of Endocrinology, Diabetes and Nutrition, Rennes, France
- CHU de Rennes, CIC INSERM 1414, Rennes, France
- Isabelle Guilhem, MD, MSc, service d’Endocrinologie-Diabétologie-Nutrition, CHU de Rennes, hôpital sud, 16 boulevard de Bulgarie, 35203 Rennes cedex, France.
| | - Maxime Penet
- CentraleSupélec/I.E.T.R, Hybrid System Control Team, Cesson-Sévigné, France
| | - Anaïs Paillard
- CHU de Rennes, Department of Endocrinology, Diabetes and Nutrition, Rennes, France
- CHU de Rennes, CIC INSERM 1414, Rennes, France
| | - Marc Carpentier
- CHU de Rennes, Département d’Information Médicale, Rennes, France
| | - Annabelle Esvant
- CHU de Rennes, Department of Endocrinology, Diabetes and Nutrition, Rennes, France
- CHU de Rennes, CIC INSERM 1414, Rennes, France
| | | | - Jean-Yves Poirier
- CHU de Rennes, Department of Endocrinology, Diabetes and Nutrition, Rennes, France
- CHU de Rennes, CIC INSERM 1414, Rennes, France
| |
Collapse
|
13
|
Turksoy K, Frantz N, Quinn L, Dumin M, Kilkus J, Hibner B, Cinar A, Littlejohn E. Automated Insulin Delivery-The Light at the End of the Tunnel. J Pediatr 2017; 186:17-28.e9. [PMID: 28396030 DOI: 10.1016/j.jpeds.2017.02.055] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 02/13/2017] [Accepted: 02/20/2017] [Indexed: 12/28/2022]
Affiliation(s)
- Kamuran Turksoy
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL
| | - Nicole Frantz
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL
| | - Laurie Quinn
- College of Nursing, University of Illinois at Chicago, Chicago, IL
| | - Magdalena Dumin
- Biological Sciences Division, University of Chicago, Chicago, IL
| | - Jennifer Kilkus
- Biological Sciences Division, University of Chicago, Chicago, IL
| | - Brooks Hibner
- Biological Sciences Division, University of Chicago, Chicago, IL
| | - Ali Cinar
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL; Biological Sciences Division, University of Chicago, Chicago, IL; Department of Chemical and Biological Engineering, Illinois Institute of Technology, Chicago, IL
| | | |
Collapse
|
14
|
Weimer J, Chen S, Peleckis A, Rickels MR, Lee I. Physiology-Invariant Meal Detection for Type 1 Diabetes. Diabetes Technol Ther 2016; 18:616-624. [PMID: 27704875 PMCID: PMC6528748 DOI: 10.1089/dia.2015.0266] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND Fully automated artificial pancreas systems require meal detectors to supplement blood glucose level regulation, where false meal detections can cause unnecessary insulin delivery with potentially fatal consequences, and missed detections may cause the patient to experience extreme hyperglycemia. Most existing meal detectors monitor various measures of glucose rate-of-change to detect meals where varying physiology and meal content complicate balancing detector sensitivity versus specificity. METHODS We developed a novel meal detector based on a minimal glucose-insulin metabolism model and show that the detector is, by design, invariant to patient-specific physiological parameters in the minimal model. Our physiological parameter-invariant (PAIN) detector achieves a near-constant false alarm rate across all individuals and is evaluated against three other major existing meal detectors on a clinical type 1 diabetes data set. RESULTS In the clinical evaluation, the PAIN-based detector achieves an 86.9% sensitivity for an average false alarm rate of two alarms per day. In addition, for all false alarm rates, the PAIN-based detector performance is significantly better than three other existing meal detectors. In addition, the evaluation results show that the PAIN-based detector uniquely (as compared with the other meal detectors) has low variance in detection and false alarm rates across all patients, without patient-specific personalization. CONCLUSIONS The PAIN-based meal detector has demonstrated better detection performance than existing meal detectors, and it has the unique strength of achieving a consistent performance across a population with varying physiology without any individual-level parameter tuning or training.
Collapse
Affiliation(s)
- James Weimer
- Department of Computer and Information Science, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Sanjian Chen
- Department of Computer and Information Science, University of Pennsylvania, Philadelphia, Pennsylvania
- Address correspondence to: Sanjian Chen, PhD, Department of Computer and Information Science, University of Pennsylvania, 3330 Walnut Street, Levine 302, Philadelphia, PA 19104
| | - Amy Peleckis
- Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Michael R. Rickels
- Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- Michael R. Rickels, MD, MS, Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, 12-134 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104
| | - Insup Lee
- Department of Computer and Information Science, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
15
|
Dehennis A, Mortellaro MA, Ioacara S. Multisite Study of an Implanted Continuous Glucose Sensor Over 90 Days in Patients With Diabetes Mellitus. J Diabetes Sci Technol 2015; 9:951-6. [PMID: 26224762 PMCID: PMC4667337 DOI: 10.1177/1932296815596760] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Continuous glucose monitoring (CGM), which enables real-time glucose display and trend information as well as real-time alarms, can improve glycemic control and quality of life in patients with diabetes mellitus. Previous reports have described strategies to extend the useable lifetime of a single sensor from 1-2 weeks to 28 days. The present multisite study describes the characterization of a sensing platform achieving 90 days of continuous use for a single, fully implanted sensor. METHOD The Senseonics CGM system is composed of a long-term implantable glucose sensor and a wearable smart transmitter. Study subjects underwent subcutaneous implantation of sensors in the upper arm. Eight-hour clinic sessions were performed every 14 days, during which sensor glucose values were compared against venous blood lab reference measurements collected every 15 minutes using mean absolute relative differences (MARDs). RESULTS All subjects (mean ± standard deviation age: 43.5 ± 11.0 years; with 10 sensors inserted in men and 14 in women) had type 1 diabetes mellitus. Most (22 of 24) sensors reported glucose values for the entire 90 days. The MARD value was 11.4 ± 2.7% (range, 8.1-19.5%) for reference glucose values between 40-400 mg/dl. There was no significant difference in MARD throughout the 90-day study (P = .31). No serious adverse events were noted. CONCLUSIONS The Senseonics CGM, composed of an implantable sensor, external smart transmitter, and smartphone app, is the first system that uses a single sensor for continuous display of accurate glucose values for 3 months.
Collapse
Affiliation(s)
| | | | - Sorin Ioacara
- Carol Davila University, Faculty of General Medicine and Elias Emergency University Hospital, Bucharest, Romania
| |
Collapse
|
16
|
Du X, Durgan CJ, Matthews DJ, Motley JR, Tan X, Pholsena K, Árnadóttir L, Castle JR, Jacobs PG, Cargill RS, Ward WK, Conley JF, Herman GS. Fabrication of a Flexible Amperometric Glucose Sensor Using Additive Processes. ECS JOURNAL OF SOLID STATE SCIENCE AND TECHNOLOGY : JSS 2015; 4:P3069-P3074. [PMID: 26634186 PMCID: PMC4664458 DOI: 10.1149/2.0101504jss] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
This study details the use of printing and other additive processes to fabricate a novel amperometric glucose sensor. The sensor was fabricated using a Au coated 12.7 μm thick polyimide substrate as a starting material, where micro-contact printing, electrochemical plating, chloridization, electrohydrodynamic jet (e-jet) printing, and spin coating were used to pattern, deposit, chloridize, print, and coat functional materials, respectively. We have found that e-jet printing was effective for the deposition and patterning of glucose oxidase inks with lateral feature sizes between ~5 to 1000 μm in width, and that the glucose oxidase was still active after printing. The thickness of the permselective layer was optimized to obtain a linear response for glucose concentrations up to 32 mM and no response to acetaminophen, a common interfering compound, was observed. The use of such thin polyimide substrates allow wrapping of the sensors around catheters with high radius of curvature ~250 μm, where additive and microfabrication methods may allow significant cost reductions.
Collapse
Affiliation(s)
- Xiaosong Du
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| | - Christopher J. Durgan
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| | - David J. Matthews
- School of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon 97331, USA
| | - Joshua R. Motley
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| | - Xuebin Tan
- School of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon 97331, USA
| | - Kovit Pholsena
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| | - Líney Árnadóttir
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| | | | - Peter G. Jacobs
- Pacific Diabetes Technologies, Portland, Oregon 97201, USA
- Oregon Health & Science University, Portland, Oregon 97239, USA
| | | | | | - John F. Conley
- School of Electrical Engineering and Computer Science, Oregon State University, Corvallis, Oregon 97331, USA
| | - Gregory S. Herman
- School of Chemical, Biological, and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, USA
| |
Collapse
|
17
|
El Youssef J, Castle JR, Bakhtiani PA, Haidar A, Branigan DL, Breen M, Ward WK. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care 2014; 37:3054-60. [PMID: 25139882 PMCID: PMC4207205 DOI: 10.2337/dc14-0803] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Glucagon delivery in closed-loop control of type 1 diabetes is effective in minimizing hypoglycemia. However, high insulin concentration lowers the hyperglycemic effect of glucagon, and small doses of glucagon in this setting are ineffective. There are no studies clearly defining the relationship between insulin levels, subcutaneous glucagon, and blood glucose. RESEARCH DESIGN AND METHODS Using a euglycemic clamp technique in 11 subjects with type 1 diabetes, we examined endogenous glucose production (EGP) of glucagon (25, 75, 125, and 175 μg) at three insulin infusion rates (0.016, 0.032, and 0.05 units/kg/h) in a randomized, crossover study. Infused 6,6-dideuterated glucose was measured every 10 min, and EGP was determined using a validated glucoregulatory model. Area under the curve (AUC) for glucose production was the primary outcome, estimated over 60 min. RESULTS At low insulin levels, EGP rose proportionately with glucagon dose, from 5 ± 68 to 112 ± 152 mg/kg (P = 0.038 linear trend), whereas at high levels, there was no increase in glucose output (19 ± 53 to 26 ± 38 mg/kg, P = NS). Peak glucagon serum levels and AUC correlated well with dose (r2 = 0.63, P < 0.001), as did insulin levels with insulin infusion rates (r2 = 0.59, P < 0.001). CONCLUSIONS EGP increases steeply with glucagon doses between 25 and 175 μg at lower insulin infusion rates. However, high insulin infusion rates prevent these doses of glucagon from significantly increasing glucose output and may reduce glucagon effectiveness in preventing hypoglycemia when used in the artificial pancreas.
Collapse
Affiliation(s)
| | | | | | - Ahmad Haidar
- Institut de Recherches Cliniques de Montréal, Montreal, Canada
| | | | | | - W Kenneth Ward
- Oregon Health & Science University, Portland, OR Legacy Health, Portland, OR
| |
Collapse
|
18
|
Elleri D, Maltoni G, Allen JM, Nodale M, Kumareswaran K, Leelarathna L, Thabit H, Caldwell K, Wilinska ME, Calhoun P, Kollman C, Dunger DB, Hovorka R. Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes Metab 2014; 16:1174-8. [PMID: 24909206 PMCID: PMC4192111 DOI: 10.1111/dom.12324] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Revised: 04/22/2014] [Accepted: 06/02/2014] [Indexed: 11/27/2022]
Abstract
We evaluated the safety and efficacy of closed-loop therapy with meal announcement during reduction and omission of meal insulin boluses in adolescents with type 1 diabetes (T1D). Twelve adolescents with T1D [six male; mean (s.d.) age 15.9 (1.8) years; mean (s.d.) glycated haemoglobin (HbA1c) 77 (27) mmol/mol] were studied in a randomized crossover study comparing closed-loop therapy with meal announcement with conventional pump therapy over two 24-h stays at a clinical research facility. Identical meals were given on both occasions. The evening meal insulin bolus was calculated to cover half of the carbohydrate content of the meal and no bolus was delivered for lunch. Plasma glucose levels were in the target range of 3.9-10 mmol/l for a median [interquartile range (IQR)] of 74 (55,86)% of the time during closed-loop therapy with meal announcement and for 62 (49,75)% of the time during conventional therapy (p = 0.26). Median (IQR) time spent with plasma glucose levels > 10 mmol/l [23 (13,39) vs. 27 (10,50)%; p = 0.88] or < 3.9 mmol/l [1(0,4) vs. 5 (1,10)%; p = 0.24] and mean [standard deviation (SD)] glucose levels [8.0 (7.6,9.3) vs. 7.7 (6.6,10.1) mmol/l, p = 0.79] were also similar. In conclusion, these results assist home testing of closed-loop delivery with meal announcement in adolescents with poorly controlled T1D who miscalculate or miss meal insulin boluses.
Collapse
Affiliation(s)
- Daniela Elleri
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Giulio Maltoni
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Janet M Allen
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Marianna Nodale
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | | | | | - Hood Thabit
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Karen Caldwell
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Malgorzata E Wilinska
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | | | | | - David B Dunger
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| | - Roman Hovorka
- Department of Paediatrics, University of Cambridge, Cambridge, UK
- Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK
| |
Collapse
|
19
|
Aathira R, Jain V. Advances in management of type 1 diabetes mellitus. World J Diabetes 2014; 5:689-696. [PMID: 25317246 PMCID: PMC4138592 DOI: 10.4239/wjd.v5.i5.689] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 06/18/2014] [Accepted: 07/17/2014] [Indexed: 02/05/2023] Open
Abstract
Treatment of type 1 diabetes mellitus has always posed a challenge to balance hyperglycemia control with hypoglycemia episodes. The quest for newer therapies is continuing and this review attempts to outline the recent developments. The insulin molecule itself has got moulded into different analogues by minor changes in its structure to ensure well controlled delivery, stable half-lives and lesser side effects. Insulin delivery systems have also consistently undergone advances from subcutaneous injections to continuous infusion to trials of inhalational delivery. Continuous glucose monitoring systems are also becoming more accurate and user friendly. Smartphones have also made their entry into therapy of diabetes by integrating blood glucose levels and food intake with calculated adequate insulin required. Artificial pancreas has enabled to a certain extent to close the loop between blood glucose level and insulin delivery with devices armed with meal and exercise announcements, dual hormone delivery and pramlintide infusion. Islet, pancreas-kidney and stem cells transplants are also being attempted though complete success is still a far way off. Incorporating insulin gene and secretary apparatus is another ambitious leap to achieve insulin independence though the search for the ideal vector and target cell is still continuing. Finally to stand up to the statement, prevention is better than cure, immunological methods are being investigated to be used as vaccine to prevent the onset of diabetes mellitus.
Collapse
|
20
|
Bevier WC, Fuller SM, Fuller RP, Rubin RR, Dassau E, Doyle FJ, Jovanovič L, Zisser HC. Artificial pancreas (AP) clinical trial participants' acceptance of future AP technology. Diabetes Technol Ther 2014; 16:590-5. [PMID: 24811147 PMCID: PMC4135316 DOI: 10.1089/dia.2013.0365] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND Artificial pancreas (AP) systems are currently an active field of diabetes research. This pilot study examined the attitudes of AP clinical trial participants toward future acceptance of the technology, having gained firsthand experience. SUBJECTS AND METHODS After possible influencers of AP technology adoption were considered, a 34-question questionnaire was developed. The survey assessed current treatment satisfaction, dimensions of clinical trial participant motivation, and variables of the technology acceptance model (TAM). Forty-seven subjects were contacted to complete the survey. The reliability of the survey scales was tested using Cronbach's α. The relationship of the factors to the likelihood of AP technology adoption was explored using regression analysis. RESULTS Thirty-six subjects (76.6%) completed the survey. Of the respondents, 86.1% were either highly likely or likely to adopt the technology once available. Reliability analysis of the survey dimensions revealed good internal consistency, with scores of >0.7 for current treatment satisfaction, convenience (motivation), personal health benefit (motivation), perceived ease of use (TAM), and perceived usefulness (TAM). Linear modeling showed that future acceptance of the AP was significantly associated with TAM and the motivation variables of convenience plus the individual item benefit to others (R(2)=0.26, P=0.05). When insulin pump and continuous glucose monitor use were added, the model significance improved (R(2)=0.37, P=0.02). CONCLUSIONS This pilot study demonstrated that individuals with direct AP technology experience expressed high likelihood of future acceptance. Results support the factors of personal benefit, convenience, perceived usefulness, and perceived ease of use as reliable scales that suggest system adoption in this highly motivated patient population.
Collapse
Affiliation(s)
- Wendy C. Bevier
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Serena M. Fuller
- Department of Family and Consumer Sciences, University of Arkansas Division of Agriculture Research and Extension, Little Rock, Arkansas
| | - Ryan P. Fuller
- Department of Speech Communication, University of Arkansas at Little Rock, Little Rock, Arkansas
| | - Richard R. Rubin
- Departments of Medicine and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Eyal Dassau
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, California
- Institute for Collaborative Biotechnologies, University of California Santa Barbara, Santa Barbara, California
| | - Francis J. Doyle
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, California
- Institute for Collaborative Biotechnologies, University of California Santa Barbara, Santa Barbara, California
| | - Lois Jovanovič
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, California
- Biomolecular Science & Engineering Program, University of California Santa Barbara, Santa Barbara, California
| | - Howard C. Zisser
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, California
| |
Collapse
|
21
|
Liu SW, Huang HP, Lin CH, Chien IL. Modified control algorithms for patients with type 1 diabetes mellitus undergoing exercise. J Taiwan Inst Chem Eng 2014. [DOI: 10.1016/j.jtice.2014.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
22
|
Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol 2014; 8:1011-7. [PMID: 25030181 PMCID: PMC4455387 DOI: 10.1177/1932296814542153] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 µg + insulin, (3) pramlintide 30 µg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3% (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P < .03) and pramlintide (P > .05). Glucagon suppression was statistically significant with exenatide (P < .03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.
Collapse
Affiliation(s)
| | - Neesha Ramchandani
- Division of Pediatric Endocrinology and Diabetes, Montefiore Medical Center, Bronx, NY, USA
| | - Jeniece Trast
- Division of Pediatric Endocrinology and Diabetes, Montefiore Medical Center, Bronx, NY, USA
| | | | - Rubina A Heptulla
- Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
23
|
Turksoy K, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive identification and control for artificial pancreas systems. IEEE Trans Biomed Eng 2014; 61:883-91. [PMID: 24557689 DOI: 10.1109/tbme.2013.2291777] [Citation(s) in RCA: 129] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A constrained weighted recursive least squares method is proposed to provide recursive models with guaranteed stability and better performance than models based on regular identification methods in predicting the variations of blood glucose concentration in patients with Type 1 Diabetes. Use of physiological information from a sports armband improves glucose concentration prediction and enables earlier recognition of the effects of physical activity on glucose concentration. Generalized predictive controllers (GPC) based on these recursive models are developed. The performance of GPC for artificial pancreas systems is illustrated by simulations with UVa-Padova simulator and clinical studies. The controllers developed are good candidates for artificial pancreas systems with no announcements from patients.
Collapse
|
24
|
Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, Doyle FJ. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014; 37:1789-96. [PMID: 24929429 PMCID: PMC4067397 DOI: 10.2337/dc13-2076] [Citation(s) in RCA: 125] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE We estimate the effect size of hypoglycemia risk reduction on closed-loop control (CLC) versus open-loop (OL) sensor-augmented insulin pump therapy in supervised outpatient setting. RESEARCH DESIGN AND METHODS Twenty patients with type 1 diabetes initiated the study at the Universities of Virginia, Padova, and Montpellier and Sansum Diabetes Research Institute; 18 completed the entire protocol. Each patient participated in two 40-h outpatient sessions, CLC versus OL, in randomized order. Sensor (Dexcom G4) and insulin pump (Tandem t:slim) were connected to Diabetes Assistant (DiAs)-a smartphone artificial pancreas platform. The patient operated the system through the DiAs user interface during both CLC and OL; study personnel supervised on site and monitored DiAs remotely. There were no dietary restrictions; 45-min walks in town and restaurant dinners were included in both CLC and OL; alcohol was permitted. RESULTS The primary outcome-reduction in risk for hypoglycemia as measured by the low blood glucose (BG) index (LGBI)-resulted in an effect size of 0.64, P = 0.003, with a twofold reduction of hypoglycemia requiring carbohydrate treatment: 1.2 vs. 2.4 episodes/session on CLC versus OL (P = 0.02). This was accompanied by a slight decrease in percentage of time in the target range of 3.9-10 mmol/L (66.1 vs. 70.7%) and increase in mean BG (8.9 vs. 8.4 mmol/L; P = 0.04) on CLC versus OL. CONCLUSIONS CLC running on a smartphone (DiAs) in outpatient conditions reduced hypoglycemia and hypoglycemia treatments when compared with sensor-augmented pump therapy. This was accompanied by marginal increase in average glycemia resulting from a possible overemphasis on hypoglycemia safety.
Collapse
Affiliation(s)
- Boris P Kovatchev
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Eric Renard
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital, INSERM Clinical Investigation Center 1001, Institute of Functional Genomics, CNRS UMR 5203, INSERM U661, University of Montpellier 1, Montpellier, France
| | - Claudio Cobelli
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | | | - Patrick Keith-Hynes
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Stacey M Anderson
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Sue A Brown
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Daniel R Chernavvsky
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Marc D Breton
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Lloyd B Mize
- Center for Diabetes Technology and Department of Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA
| | - Anne Farret
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital, INSERM Clinical Investigation Center 1001, Institute of Functional Genomics, CNRS UMR 5203, INSERM U661, University of Montpellier 1, Montpellier, France
| | - Jérôme Place
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital, INSERM Clinical Investigation Center 1001, Institute of Functional Genomics, CNRS UMR 5203, INSERM U661, University of Montpellier 1, Montpellier, France
| | - Daniela Bruttomesso
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | - Simone Del Favero
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | - Federico Boscari
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | - Silvia Galasso
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | - Angelo Avogaro
- Department of Information Engineering and Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy
| | - Lalo Magni
- Department of Systems Engineering, University of Pavia, Pavia, Italy
| | - Federico Di Palma
- Department of Systems Engineering, University of Pavia, Pavia, Italy
| | - Chiara Toffanin
- Department of Systems Engineering, University of Pavia, Pavia, Italy
| | - Mirko Messori
- Department of Systems Engineering, University of Pavia, Pavia, Italy
| | - Eyal Dassau
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA
| | - Francis J Doyle
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA
| |
Collapse
|
25
|
Huang M, Song X. Modeling and qualitative analysis of diabetes therapies with state feedback control. INT J BIOMATH 2014. [DOI: 10.1142/s1793524514500351] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
For the therapies of diabetes mellitus, a novel mathematical model with two state impulses: impulsive injection of insulin and impulsive injection of glucagon, is proposed. To avoid hypoglycemia and hyperglycemia, the injections of insulin and glucagon are determined by closely monitoring the plasma glucose level of the patients. By using differential equation geometry theory, the existence of periodic solution and the attraction region of the system have been obtained, which ensures that injections in such an automated way can keep the blood glucose concentration under control. The simulation results verify that the better insulin injection strategy in closed-loop control is a larger dose but longer interval rather than a smaller dose but shorter interval. Besides, our numerical analysis reveals that medicine studies and practice that slow down the insulin degradation are helpful for the plasma glucose control. Our findings can provide significant guidance in both design of artificial pancreas and clinical treatment.
Collapse
Affiliation(s)
- Mingzhan Huang
- College of Mathematics and Information Science, Xinyang Normal University, Xinyang 464000, P. R. China
- Research Institute of Forest Resource Information Techniques, Chinese Academy of Forestry, Beijing 100091, P. R. China
| | - Xinyu Song
- College of Mathematics and Information Science, Xinyang Normal University, Xinyang 464000, P. R. China
| |
Collapse
|
26
|
Harvey RA, Dassau E, Bevier WC, Seborg DE, Jovanovič L, Doyle FJ, Zisser HC. Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. Diabetes Technol Ther 2014; 16:348-57. [PMID: 24471561 PMCID: PMC4029139 DOI: 10.1089/dia.2013.0231] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND This study was performed to evaluate the safety and efficacy of a fully automated artificial pancreas using zone-model predictive control (zone-MPC) with the health monitoring system (HMS) during unannounced meals and overnight and exercise periods. SUBJECTS AND METHODS A fully automated closed-loop artificial pancreas was evaluated in 12 subjects (eight women, four men) with type 1 diabetes (mean±SD age, 49.4±10.4 years; diabetes duration, 32.7±16.0 years; glycosylated hemoglobin, 7.3±1.2%). The zone-MPC controller used an a priori model that was initialized using the subject's total daily insulin. The controller was designed to keep glucose levels between 80 and 140 mg/dL. A hypoglycemia prediction algorithm, a module of the HMS, was used in conjunction with the zone controller to alert the user to consume carbohydrates if the glucose level was predicted to fall below 70 mg/dL in the next 15 min. RESULTS The average time spent in the 70-180 mg/dL range, measured by the YSI glucose and lactate analyzer (Yellow Springs Instruments, Yellow Springs, OH), was 80% for the entire session, 92% overnight from 12 a.m. to 7 a.m., and 69% and 61% for the 5-h period after dinner and breakfast, respectively. The time spent < 60 mg/dL for the entire session by YSI was 0%, with no safety events. The HMS sent appropriate warnings to prevent hypoglycemia via short and multimedia message services, at an average of 3.8 treatments per subject. CONCLUSIONS The combination of the zone-MPC controller and the HMS hypoglycemia prevention algorithm was able to safely regulate glucose in a tight range with no adverse events despite the challenges of unannounced meals and moderate exercise.
Collapse
Affiliation(s)
- Rebecca A. Harvey
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
| | - Eyal Dassau
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Institute for Collaborative Biotechnologies, University of California Santa Barbara, Santa Barbara, California
| | - Wendy C. Bevier
- Sansum Diabetes Research Institute, Santa Barbara, California
| | - Dale E. Seborg
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
| | - Lois Jovanovič
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
| | - Francis J. Doyle
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
- Institute for Collaborative Biotechnologies, University of California Santa Barbara, Santa Barbara, California
| | - Howard C. Zisser
- Sansum Diabetes Research Institute, Santa Barbara, California
- Department of Chemical Engineering, University of California, Santa Barbara, California
| |
Collapse
|
27
|
Turksoy K, Cinar A. Adaptive control of artificial pancreas systems - a review. JOURNAL OF HEALTHCARE ENGINEERING 2014; 5:1-22. [PMID: 24691384 DOI: 10.1260/2040-2295.5.1.1] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Artificial pancreas (AP) systems offer an important improvement in regulating blood glucose concentration for patients with type 1 diabetes, compared to current approaches. AP consists of sensors, control algorithms and an insulin pump. Different AP control algorithms such as proportional-integral-derivative, model-predictive control, adaptive control, and fuzzy logic control have been investigated in simulation and clinical studies in the past three decades. The variability over time and complexity of the dynamics of blood glucose concentration, unsteady disturbances such as meals, time-varying delays on measurements and insulin infusion, and noisy data from sensors create a challenging system to AP. Adaptive control is a powerful control technique that can deal with such challenges. In this paper, a review of adaptive control techniques for blood glucose regulation with an AP system is presented. The investigations and advances in technology produced impressive results, but there is still a need for a reliable AP system that is both commercially viable and appealing to patients with type 1 diabetes.
Collapse
Affiliation(s)
- Kamuran Turksoy
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA
| | - Ali Cinar
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA Department of Chemical and Biological Engineering, Illinois Institute of Technology, Chicago, IL, USA
| |
Collapse
|
28
|
Jacobs PG, El Youssef J, Castle J, Bakhtiani P, Branigan D, Breen M, Bauer D, Preiser N, Leonard G, Stonex T, Ward WK. Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Trans Biomed Eng 2014; 61:2569-81. [PMID: 24835122 DOI: 10.1109/tbme.2014.2323248] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Automated control of blood glucose in patients with type-1 diabetes has not yet been fully implemented. The aim of this study was to design and clinically evaluate a system that integrates a control algorithm with off-the-shelf subcutaneous sensors and pumps to automate the delivery of the hormones glucagon and insulin in response to continuous glucose sensor measurements. The automated component of the system runs an adaptive proportional derivative control algorithm which determines hormone delivery rates based on the sensed glucose measurements and the meal announcements by the patient. We provide details about the system design and the control algorithm, which incorporates both a fading memory proportional derivative controller (FMPD) and an adaptive system for estimating changing sensitivity to insulin based on a glucoregulatory model of insulin action. For an inpatient study carried out in eight subjects using Dexcom SEVEN PLUS sensors, prestudy HbA1c averaged 7.6, which translates to an estimated average glucose of 171 mg/dL. In contrast, during use of the automated system, after initial stabilization, glucose averaged 145 mg/dL and subjects were kept within the euglycemic range (between 70 and 180 mg/dL) for 73.1% of the time, indicating improved glycemic control. A further study on five additional subjects in which we used a newer and more reliable glucose sensor (Dexcom G4 PLATINUM) and made improvements to the insulin and glucagon pump communication system resulted in elimination of hypoglycemic events. For this G4 study, the system was able to maintain subjects' glucose levels within the near-euglycemic range for 71.6% of the study duration and the mean venous glucose level was 151 mg/dL.
Collapse
|
29
|
Abstract
The objective was to develop a closed-loop (CL) artificial pancreas (AP) control system that uses continuous measurements of glucose concentration and physiological variables, integrated with a hypoglycemia early alarm module to regulate glucose concentration and prevent hypoglycemia. Eleven open-loop (OL) and 9 CL experiments were performed. A multivariable adaptive artificial pancreas (MAAP) system was used for the first 6 CL experiments. An integrated multivariable adaptive artificial pancreas (IMAAP) system consisting of MAAP augmented with a hypoglycemia early alarm system was used during the last 3 CL experiments. Glucose values and physical activity information were measured and transferred to the controller every 10 minutes and insulin suggestions were entered to the pump manually. All experiments were designed to be close to real-life conditions. Severe hypoglycemic episodes were seen several times during the OL experiments. With the MAAP system, the occurrence of severe hypoglycemia was decreased significantly (P < .01). No hypoglycemia was seen with the IMAAP system. There was also a significant difference (P < .01) between OL and CL experiments with regard to percentage of glucose concentration (54% vs 58%) that remained within target range (70-180 mg/dl). Integration of an adaptive control and hypoglycemia early alarm system was able to keep glucose concentration values in target range in patients with type 1 diabetes. Postprandial hypoglycemia and exercise-induced hypoglycemia did not occur when this system was used. Physical activity information improved estimation of the blood glucose concentration and effectiveness of the control system.
Collapse
Affiliation(s)
- Kamuran Turksoy
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA
| | - Lauretta T Quinn
- College of Nursing, University of Illinois at Chicago, Chicago, IL, USA
| | | | - Ali Cinar
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA Department of Chemical and Biological Engineering, Illinois Institute of Technology, Chicago, IL, USA
| |
Collapse
|
30
|
El-Khatib FH, Russell SJ, Magyar KL, Sinha M, McKeon K, Nathan DM, Damiano ER. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab 2014; 99:1701-11. [PMID: 24483160 PMCID: PMC4010702 DOI: 10.1210/jc.2013-4151] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
CONTEXT A challenge for automated glycemic control in type 1 diabetes (T1D) is the large variation in insulin needs between individuals and within individuals at different times in their lives. OBJECTIVES The objectives of the study was to test the ability of a third-generation bihormonal bionic pancreas algorithm, initialized with only subject weight; to adapt automatically to the different insulin needs of adults and adolescents; and to evaluate the impact of optional, automatically adaptive meal-priming boluses. DESIGN This was a randomized controlled trial. SETTING The study was conducted at an inpatient clinical research center. PATIENTS Twelve adults and 12 adolescents with T1D participated in the study. INTERVENTIONS Subjects in each age group were randomized to automated glycemic control for 48 hours with or without automatically adaptive meal-priming boluses. MAIN OUTCOME MEASURES Mean plasma glucose (PG), time with PG less than 60 mg/dL, and insulin total daily dose were measured. RESULTS The 48-hour mean PG values with and without adaptive meal-priming boluses were 132 ± 9 vs 146 ± 9 mg/dL (P = .03) in adults and 162 ± 6 vs 175 ± 9 mg/dL (P = .01) in adolescents. Adaptive meal-priming boluses improved mean PG without increasing time spent with PG less than 60 mg/dL: 1.4% vs 2.3% (P = .6) in adults and 0.1% vs 0.1% (P = 1.0) in adolescents. Large increases in adaptive meal-priming boluses and shifts in the timing and size of automatic insulin doses occurred in adolescents. Much less adaptation occurred in adults. There was nearly a 4-fold variation in the total daily insulin dose across all cohorts (0.36-1.41 U/kg · d). CONCLUSIONS A single control algorithm, initialized only with subject weight, can quickly adapt to regulate glycemia in patients with TID and highly variable insulin requirements.
Collapse
|
31
|
Harvey RA, Dassau E, Zisser H, Seborg DE, Doyle FJ. Design of the Glucose Rate Increase Detector: A Meal Detection Module for the Health Monitoring System. J Diabetes Sci Technol 2014; 8:307-320. [PMID: 24876583 PMCID: PMC4455414 DOI: 10.1177/1932296814523881] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The Glucose Rate Increase Detector (GRID), a module of the Health Monitoring System (HMS), has been designed to operate in parallel to the glucose controller to detect meal events and safely trigger a meal bolus. The GRID algorithm was tuned on clinical data with 40-70 g CHO meals and tested on simulation data with 50-100 g CHO meals. Active closed- and open-loop protocols were executed in silico with various treatments, including automatic boluses based on a 75 g CHO meal and boluses based on simulated user input of meal size. An optional function was used to reduce the recommended bolus using recent insulin and glucose history. For closed-loop control of a 3-meal scenario (50, 75, and 100 g CHO), the GRID improved median time in the 80-180 mg/dL range by 17% and in the >180 range by 14% over unannounced meals, using an automatic bolus for a 75 g CHO meal at detection. Under open-loop control of a 75 g CHO meal, the GRID shifted the median glucose peak down by 73 mg/dL and earlier by 120 min and reduced the time >180 mg/dL by 57% over a missed-meal bolus scenario, using a full meal bolus at detection. The GRID improved closed-loop control in the presence of large meals, without increasing late postprandial hypoglycemia. Users of basal-bolus therapy could also benefit from GRID as a safety alert for missed meal corrections.
Collapse
Affiliation(s)
- Rebecca A Harvey
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
| | - Eyal Dassau
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Biomolecular Science & Engineering Program, University of California, Santa Barbara, Santa Barbara, CA, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
| | - Howard Zisser
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
| | - Dale E Seborg
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
| | - Francis J Doyle
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Biomolecular Science & Engineering Program, University of California, Santa Barbara, Santa Barbara, CA, USA Sansum Diabetes Research Institute, Santa Barbara, CA, USA
| |
Collapse
|
32
|
Bothe MK, Dickens L, Reichel K, Tellmann A, Ellger B, Westphal M, Faisal AA. The use of reinforcement learning algorithms to meet the challenges of an artificial pancreas. Expert Rev Med Devices 2014; 10:661-73. [PMID: 23972072 DOI: 10.1586/17434440.2013.827515] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Melanie K Bothe
- Fresenius Kabi Deutschland GmbH, Else-Kröner-Strasse 1, 61352 Bad Homburg, Germany
| | | | | | | | | | | | | |
Collapse
|
33
|
Ghorbani M, Bogdan P. Reducing risk of closed loop control of blood glucose in artificial pancreas using fractional calculus. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2014; 2014:4839-4842. [PMID: 25571075 DOI: 10.1109/embc.2014.6944707] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Healthcare costs in the US are among the highest in the world. Chronic diseases such as diabetes significantly contribute to these extensive costs. Despite technological advances to improve sensing and actuation devices, we still lack a coherent theory that facilitates the design and optimization of efficient and robust medical cyber-physical systems for managing chronic diseases. In this paper, we propose a mathematical model for capturing the complex dynamics of blood glucose time series (e.g., time dependent and fractal behavior) observed in real world measurements via fractional calculus concepts. Building upon our time dependent fractal model, we propose a novel model predictive controller for an artificial pancreas that regulates insulin injection. We verify the accuracy of our controller by comparing it to conventional non-fractal models using real world measurements and show how the nonlinear optimal controller based on fractal calculus concepts is superior to non-fractal controllers in terms of average risk index and prediction accuracy.
Collapse
|
34
|
Bakhtiani PA, Zhao LM, El Youssef J, Castle JR, Ward WK. A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes Metab 2013; 15:1065-70. [PMID: 23602044 PMCID: PMC3766424 DOI: 10.1111/dom.12107] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 01/07/2013] [Accepted: 03/27/2013] [Indexed: 01/30/2023]
Abstract
Since the discovery of insulin, great progress has been made to improve the accuracy and safety of automated insulin delivery systems to help patients with type 1 diabetes achieve their treatment goals without causing hypoglycaemia. In recent years, bioengineering technology has greatly advanced diabetes management, with the development of blood glucose meters, continuous glucose monitors, insulin pumps and control systems for automatic delivery of one or more hormones. New insulin analogues have improved subcutaneous absorption characteristics, but do not completely eliminate the risk of hypoglycaemia. Insulin effect is counteracted by glucagon in non-diabetic individuals, while glucagon secretion in those with type 1 diabetes is impaired. The use of glucagon in the artificial pancreas is therefore a logical and feasible option for preventing and treating hypoglycaemia. However, commercially available glucagon is not stable in aqueous solution for long periods, forming potentially cytotoxic fibrils that aggregate quickly. Therefore, a more stable formulation of glucagon is needed for long-term use and storage in a bi-hormonal pump. In addition, a model of glucagon action in type 1 diabetes is lacking, further limiting the inclusion of glucagon into systems employing model-assisted control. As a result, although several investigators have been working to help develop bi-hormonal systems for patients with type 1 diabetes, most continue to utilize single hormone systems employing only insulin. This article seeks to focus on the attributes of glucagon and its use in bi-hormonal systems.
Collapse
Affiliation(s)
- P A Bakhtiani
- Harold Schnitzer Diabetes Center, Oregon Health and Science University, Portland, OR, USA
| | | | | | | | | |
Collapse
|
35
|
Steil GM. Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control. J Diabetes Sci Technol 2013; 7:1621-31. [PMID: 24351189 PMCID: PMC3876341 DOI: 10.1177/193229681300700623] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Closed-loop insulin delivery continues to be one of most promising strategies for achieving near-normal control of blood glucose levels in individuals with diabetes. Of the many components that need to work well for the artificial pancreas to be advanced into routine use, the algorithm used to calculate insulin delivery has received a substantial amount of attention. Most of that attention has focused on the relative merits of proportional-integral-derivative versus model-predictive control. A meta-analysis of the clinical data obtained in studies performed to date with these approaches is conducted here, with the objective of determining if there is a trend for one approach to be performing better than the other approach. Challenges associated with implementing each approach are reviewed with the objective of determining how these approaches might be improved. Results of the meta-analysis, which focused predominantly on the breakfast meal response, suggest that to date, the two approaches have performed similarly. However, uncontrolled variables among the various studies, and the possibility that future improvements could still be effected in either approach, limit the validity of this conclusion. It is suggested that a more detailed examination of the challenges associated with implementing each approach be conducted.
Collapse
Affiliation(s)
- Garry M Steil
- Children's Hospital Boston, 300 Longwood Ave., Boston, MA 02215. garry.steil@childrens/harvard.edu
| |
Collapse
|
36
|
Abstract
The relative merits of model predictive control (MPC) and proportional-integral-derivative (PID) control are discussed, with the end goal of a closed-loop artificial pancreas (AP). It is stressed that neither MPC nor PID are single algorithms, but rather are approaches or strategies that may be implemented very differently by different engineers. The primary advantages to MPC are that (i) constraints on the insulin delivery rate (and/or insulin on board) can be explicitly included in the control calculation; (ii) it is a general framework that makes it relatively easy to include the effect of meals, exercise, and other events that are a function of the time of day; and (iii) it is flexible enough to include many different objectives, from set-point tracking (target) to zone (control to range). In the end, however, it is recognized that the control algorithm, while important, represents only a portion of the effort required to develop a closed-loop AP. Thus, any number of algorithms/approaches can be successful--the engineers involved in the design must have experience with the particular technique, including the important experience of implementing the algorithm in human studies and not simply through simulation studies.
Collapse
Affiliation(s)
- B Wayne Bequette
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, NY 12180-3590.
| |
Collapse
|
37
|
Keith-Hynes P, Guerlain S, Mize B, Hughes-Karvetski C, Khan M, McElwee-Malloy M, Kovatchev BP. DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J Diabetes Sci Technol 2013; 7:1416-26. [PMID: 24351168 PMCID: PMC3876320 DOI: 10.1177/193229681300700602] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
BACKGROUND Recent in-hospital studies of artificial pancreas (AP) systems have shown promising results in improving glycemic control in patients with type 1 diabetes mellitus. The next logical step in AP development is to conduct transitional outpatient clinical trials with a mobile system that is controlled by the patient. In this article, we present the user interface (UI) of the Diabetes Assistant (DiAs), an experimental smartphone-based mobile AP system, and describe the reactions of a round of focus groups to the UI. This work is an initial inquiry involving a relatively small number of potential users, many of whom had never seen an AP system before, and the results should be understood in that light. METHODS We began by considering how the UI of an AP system could be designed to make use of the familiar touch-based graphical UI of a consumer smartphone. After developing a working prototype UI, we enlisted a human factors specialist to perform a heuristic expert analysis. Next we conducted a formative evaluation of the UI through a series of three focus groups with N = 13 potential end users as participants. The UI was modified based upon the results of these studies, and the resulting DiAs system was used in transitional outpatient AP studies of adults in the United States and Europe. RESULTS The DiAs UI was modified based on focus group feedback from potential users. The DiAs was subsequently used in JDRF- and AP@Home-sponsored transitional outpatient AP studies in the United States and Europe by 40 subjects for 2400 h with no adverse events. CONCLUSIONS Adult patients with type 1 diabetes mellitus are able to control an AP system successfully using a patient-centric UI on a commercial smartphone in a transitional outpatient environment.
Collapse
Affiliation(s)
- Patrick Keith-Hynes
- Center for Diabetes Technology Research, University of Virginia, 617 West Main St., 4th Floor, Charlottesville, VA 22903.
| | | | | | | | | | | | | |
Collapse
|
38
|
Place J, Robert A, Ben Brahim N, Keith-Hynes P, Farret A, Pelletier MJ, Buckingham B, Breton M, Kovatchev B, Renard E. DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol 2013; 7:1427-35. [PMID: 24351169 PMCID: PMC3876321 DOI: 10.1177/193229681300700603] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Developments in an artificial pancreas (AP) for patients with type 1 diabetes have allowed a move toward performing outpatient clinical trials. "Home-like" environment implies specific protocol and system adaptations among which the introduction of remote monitoring is meaningful. We present a novel tool allowing multiple patients to monitor AP use in home-like settings. METHODS We investigated existing systems, performed interviews of experienced clinical teams, listed required features, and drew several mockups of the user interface. The resulting application was tested on the bench before it was used in three outpatient studies representing 3480 h of remote monitoring. RESULTS Our tool, called DiAs Web Monitoring (DWM), is a web-based application that ensures reception, storage, and display of data sent by AP systems. Continuous glucose monitoring (CGM) and insulin delivery data are presented in a colored chart to facilitate reading and interpretation. Several subjects can be monitored simultaneously on the same screen, and alerts are triggered to help detect events such as hypoglycemia or CGM failures. In the third trial, DWM received approximately 460 data per subject per hour: 77% for log messages, 5% for CGM data. More than 97% of transmissions were achieved in less than 5 min. CONCLUSIONS Transition from a hospital setting to home-like conditions requires specific AP supervision to which remote monitoring systems can contribute valuably. DiAs Web Monitoring worked properly when tested in our outpatient studies. It could facilitate subject monitoring and even accelerate medical and technical assessment of the AP. It should now be adapted for long-term studies with an enhanced notification feature.
Collapse
Affiliation(s)
- Jérôme Place
- Département d'Endocrinologie, Diabète et Nutrition, Hôpital Lapeyronie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Schmidt S, Boiroux D, Duun-Henriksen AK, Frøssing L, Skyggebjerg O, Jørgensen JB, Poulsen NK, Madsen H, Madsbad S, Nørgaard K. Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience. J Diabetes Sci Technol 2013; 7:1255-64. [PMID: 24124952 PMCID: PMC3876369 DOI: 10.1177/193229681300700515] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND To improve type 1 diabetes mellitus (T1DM) management, we developed a model predictive control (MPC) algorithm for closed-loop (CL) glucose control based on a linear second-order deterministic-stochastic model. The deterministic part of the model is specified by three patient-specific parameters: insulin sensitivity factor, insulin action time, and basal insulin infusion rate. The stochastic part is identical for all patients but identified from data from a single patient. Results of the first clinical feasibility test of the algorithm are presented. METHODS We conducted two randomized crossover studies. Study 1 compared CL with open-loop (OL) control. Study 2 compared glucose control after CL initiation in the euglycemic (CL-Eu) and hyperglycemic (CL-Hyper) ranges, respectively. Patients were studied from 22:00-07:00 on two separate nights. RESULTS Each study included six T1DM patients (hemoglobin A1c 7.2% ± 0.4%). In study 1, hypoglycemic events (plasma glucose < 54 mg/dl) occurred on two OL and one CL nights. Average glucose from 22:00-07:00 was 90 mg/dl [74-146 mg/dl; median (interquartile range)] during OL and 108 mg/dl (101-128 mg/dl) during CL (determined by continuous glucose monitoring). However, median time spent in the range 70-144 mg/dl was 67.9% (3.0-73.3%) during OL and 80.8% (70.5-89.7%) during CL. In study 2, there was one episode of hypoglycemia with plasma glucose <54 mg/dl in a CL-Eu night. Mean glucose from 22:00-07:00 and time spent in the range 70-144 mg/dl were 121 mg/dl (117-133 mg/dl) and 69.0% (30.7-77.9%) in CL-Eu and 149 mg/dl (140-193 mg/dl) and 48.2% (34.9-72.5%) in CL-Hyper, respectively. CONCLUSIONS This study suggests that our novel MPC algorithm can safely and effectively control glucose overnight, also when CL control is initiated during hyperglycemia.
Collapse
Affiliation(s)
- Signe Schmidt
- Department of Endocrinology, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Stahl F, Johansson R, Renard E. Bayesian combination of multiple plasma glucose predictors. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2013; 2012:2839-44. [PMID: 23366516 DOI: 10.1109/embc.2012.6346555] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
This paper presents a novel on-line approach of merging multiple different predictors of plasma glucose into a single optimized prediction. Various different predictors are merged by recursive weighting into a single prediction using regularized optimization. The approach is evaluated on 12 data sets of type I diabetes data, using three parallel predictors. The performance of the combined prediction is better, or in par, with the best predictor for each evaluated data set. The results suggest that the outlined method could be a suitable way to improve prediction performance when using multiple predictors, or as a means to reduce the risk associated with definite a priori model selection.
Collapse
Affiliation(s)
- F Stahl
- Dept. Automatic Control, Lund University, PO Box 118, SE22100 Lund Sweden.
| | | | | |
Collapse
|
41
|
Capozzi D, Lanzola G. A generic telemedicine infrastructure for monitoring an artificial pancreas trial. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2013; 110:343-353. [PMID: 23415079 DOI: 10.1016/j.cmpb.2013.01.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Revised: 11/06/2012] [Accepted: 01/13/2013] [Indexed: 06/01/2023]
Abstract
Telemedicine systems are seen as a possible solution for the remote monitoring of physiological parameters and can be particularly useful for chronic patients treated at home. Implementing those systems however has always required spending a great effort on the underlying infrastructure instead of focusing on the application cores as perceived by their users. This paper proposes an abstract unifying infrastructure for telemedicine services which is loosely based on the multi-agent paradigm. It provides the capability of transferring to the clinic any remotely acquired information, and possibly sending back updates to the patient. The infrastructure is a layered one, with the bottom layer acting at the data level and implemented in terms of a software library targeting a wide set of hardware devices. On top of this infrastructure several services can be written shaping the functionality of the telemedicine application while at the highest level, adhering to a simple agent model, it is possible to reuse those functional components porting the application to different platforms. The infrastructure has been successfully used for implementing a telemonitoring service for a randomized controlled study aimed at testing the effectiveness of the artificial pancreas as a treatment within the AP@home project funded by the European Union.
Collapse
Affiliation(s)
- Davide Capozzi
- Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy.
| | | |
Collapse
|
42
|
Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Pediatr Diabetes 2013; 14:159-67. [PMID: 23448393 DOI: 10.1111/pedi.12025] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Revised: 01/07/2013] [Accepted: 01/09/2013] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Tight glucose control is needed to prevent long-term diabetes complications; this is hindered by the risk of hypoglycemia, especially at night. OBJECTIVE To assess the safety and efficacy of the closed-loop MD-Logic Artificial Pancreas (MDLAP), controlling nocturnal glucose levels in patients with type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS This was a randomized, multicenter, multinational, crossover trial conducted in Slovenia, Germany, and Israel. Twelve patients with T1DM (age 23.8 ± 15.6 yr; duration of diabetes 13.5 ± 11.9 yr; A1c 8.1 ± 0.8%, mean ± SD) were randomly assigned to participate in two sequential overnight sessions: one using continuous subcutaneous insulin infusion (CSII) and the other, closed-loop insulin delivery by MDLAP. The primary outcome was the number of hypoglycemic events below 63 mg/dL. Endpoints analyses were based on sensor glucose readings. RESULTS Three events of nocturnal hypoglycemia occurred during CSII and none during the closed-loop control (p = 0.18). The percentage of time spent in the near normal range of 63-140 mg/dL was significantly higher in the overnight closed-loop sessions [76% (54-85)] than during CSII therapy [29% (11-44)] [p = 0.02, median (interquartile range)]. The mean overnight glucose level was reduced by 36 mg/dL with closed-loop insulin delivery (p = 0.02) with a significantly less glucose variability when compared with the CSII nights (p < 0.001). CONCLUSION The results of this study demonstrate the ability of the MDLAP to safely improve overnight glucose control without increased risk of hypoglycemia in patients with T1DM at three different national, geographic, and clinical centers (ClinicalTrials.gov number, NCT 01238406).
Collapse
Affiliation(s)
- Revital Nimri
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kovacs L, Szalay P, Almássy Z, Barkai L. Applicability results of a nonlinear model-based robust blood glucose control algorithm. J Diabetes Sci Technol 2013; 7:708-16. [PMID: 23759404 PMCID: PMC3869139 DOI: 10.1177/193229681300700316] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
INTRODUCTION Generating optimal control algorithms for an artificial pancreas is an intensively researched problem. The available models are all nonlinear and rather complex. Model predictive control or run-to-run-based methodologies have proven to be efficient solutions for individualized treatment of type 1 diabetes mellitus (T1DM). However, the controller has to ensure safety and stability under all circumstances. Robust control methods seek to provide this safety and guarantee to handle even the worst-case situations and, hence, to generalize and complement results obtained by individualized control algorithms. METHODS Modern robust (e.g., Hinf) control is a linear model-based methodology that we have combined with the nonlinear model-based linear parameter varying technique. The control algorithm was designed on the high-complexity modified nonlinear glucose-insulin model of Sorensen, and it was compared step-by-step with linear model-based Hinf control results published in the literature. The applicability of the developed algorithm was tested first on a control cohort of 10 healthy persons' oral glucose tolerance test results and then on a large meal absorption profile adapted from the literature. In the latter case, two preliminary virtual patients were generated based on 1-1 week real continuous glucose monitor measurements. RESULTS We have found that the algorithm avoids hypoglycemia (not caused by physical activity or stress) independently from the considered absorption profiles. CONCLUSION Use of hard constraints proved their efficiency in fitting blood glucose level within a defined interval. However, in the future, more data of different T1DM patients will be collected and tested, including dynamic absorption model and in silico tests on validated simulators.
Collapse
Affiliation(s)
- Levente Kovacs
- Óbuda University, John von Neumann Faculty of Informatics, Bécsi út 96/b, Budapest, Hungary.
| | | | | | | |
Collapse
|
44
|
Turksoy K, Bayrak ES, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement. Diabetes Technol Ther 2013; 15:386-400. [PMID: 23544672 PMCID: PMC3643229 DOI: 10.1089/dia.2012.0283] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Accurate closed-loop control is essential for developing artificial pancreas (AP) systems that adjust insulin infusion rates from insulin pumps. Glucose concentration information from continuous glucose monitoring (CGM) systems is the most important information for the control system. Additional physiological measurements can provide valuable information that can enhance the accuracy of the control system. Proportional-integral-derivative control and model predictive control have been popular in AP development. Their implementations to date rely on meal announcements (e.g., bolus insulin dose based on insulin:carbohydrate ratios) by the user. Adaptive control techniques provide a powerful alternative that do not necessitate any meal or activity announcements. MATERIALS AND METHODS Adaptive control systems based on the generalized predictive control framework are developed by extending the recursive modeling techniques. Physiological signals such as energy expenditure and galvanic skin response are used along with glucose measurements to generate a multiple-input-single-output model for predicting future glucose concentrations used by the controller. Insulin-on-board (IOB) is also estimated and used in control decisions. The controllers were tested with clinical studies that include seven cases with three different patients with type 1 diabetes for 32 or 60 h without any meal or activity announcements. RESULTS The adaptive control system kept glucose concentration in the normal preprandial and postprandial range (70-180 mg/dL) without any meal or activity announcements during the test period. After IOB estimation was added to the control system, mild hypoglycemic episodes were observed only in one of the four experiments. This was reflected in a plasma glucose value of 56 mg/dL (YSI 2300 STAT; Yellow Springs Instrument, Yellow Springs, OH) and a CGM value of 63 mg/dL). CONCLUSIONS Regulation of blood glucose concentration with an AP using adaptive control techniques was successful in clinical studies, even without any meal and physical activity announcement.
Collapse
Affiliation(s)
- Kamuran Turksoy
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois
| | - Elif Seyma Bayrak
- Department of Chemical and Biological Engineering, Illinois Institute of Technology, Chicago, Illinois
| | - Lauretta Quinn
- College of Nursing, University of Illinois Chicago, Chicago, Illinois
| | | | - Ali Cinar
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois
- Department of Chemical and Biological Engineering, Illinois Institute of Technology, Chicago, Illinois
| |
Collapse
|
45
|
Dassau E, Zisser H, Harvey RA, Percival MW, Grosman B, Bevier W, Atlas E, Miller S, Nimri R, Jovanovic L, Doyle FJ. Clinical evaluation of a personalized artificial pancreas. Diabetes Care 2013; 36. [PMID: 23193210 PMCID: PMC3609541 DOI: 10.2337/dc12-0948] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE An artificial pancreas (AP) that automatically regulates blood glucose would greatly improve the lives of individuals with diabetes. Such a device would prevent hypo- and hyperglycemia along with associated long- and short-term complications as well as ease some of the day-to-day burden of frequent blood glucose measurements and insulin administration. RESEARCH DESIGN AND METHODS We conducted a pilot clinical trial evaluating an individualized, fully automated AP using commercial devices. Two trials (n = 22, n(subjects) = 17) were conducted using a multiparametric formulation of model predictive control and an insulin-on-board algorithm such that the control algorithm, or "brain," can be embedded on a chip as part of a future mobile device. The protocol evaluated the control algorithm for three main challenges: 1) normalizing glycemia from various initial glucose levels, 2) maintaining euglycemia, and 3) overcoming an unannounced meal of 30 ± 5 g carbohydrates. RESULTS Initial glucose values ranged from 84-251 mg/dL. Blood glucose was kept in the near-normal range (80-180 mg/dL) for an average of 70% of the trial time. The low and high blood glucose indices were 0.34 and 5.1, respectively. CONCLUSIONS These encouraging short-term results reveal the ability of a control algorithm tailored to an individual's glucose characteristics to successfully regulate glycemia, even when faced with unannounced meals or initial hyperglycemia. To our knowledge, this represents the first truly fully automated multiparametric model predictive control algorithm with insulin-on-board that does not rely on user intervention to regulate blood glucose in individuals with type 1 diabetes.
Collapse
Affiliation(s)
- Eyal Dassau
- Department of Chemical Engineering, University of California, Santa Barbara, California, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Revert A, Garelli F, Pico J, De Battista H, Rossetti P, Vehi J, Bondia J. Safety auxiliary feedback element for the artificial pancreas in type 1 diabetes. IEEE Trans Biomed Eng 2013; 60:2113-22. [PMID: 23428611 DOI: 10.1109/tbme.2013.2247602] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The artificial pancreas aims at the automatic delivery of insulin for glycemic control in patients with type 1 diabetes, i.e., closed-loop glucose control. One of the challenges of the artificial pancreas is to avoid controller overreaction leading to hypoglycemia, especially in the late postprandial period. In this study, an original proposal based on sliding mode reference conditioning ideas is presented as a way to reduce hypoglycemia events induced by a closed-loop glucose controller. The method is inspired in the intuitive advantages of two-step constrained control algorithms. It acts on the glucose reference sent to the main controller shaping it so as to avoid violating given constraints on the insulin-on-board. Some distinctive features of the proposed strategy are that 1) it provides a safety layer which can be adjusted according to medical criteria; 2) it can be added to closed-loop controllers of any nature; 3) it is robust against sensor failures and overestimated prandial insulin doses; and 4) it can handle nonlinear models. The method is evaluated in silico with the ten adult patients available in the FDA-accepted UVA simulator.
Collapse
Affiliation(s)
- A Revert
- Instituto Universitario de Automática e Informática Industrial, Universitat Politècnica de València, Valencia 46022, Spain.
| | | | | | | | | | | | | |
Collapse
|
47
|
Daskalaki E, Diem P, Mougiakakou SG. An Actor-Critic based controller for glucose regulation in type 1 diabetes. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2013; 109:116-125. [PMID: 22502983 DOI: 10.1016/j.cmpb.2012.03.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Revised: 02/29/2012] [Accepted: 03/08/2012] [Indexed: 05/31/2023]
Abstract
A novel adaptive approach for glucose control in individuals with type 1 diabetes under sensor-augmented pump therapy is proposed. The controller, is based on Actor-Critic (AC) learning and is inspired by the principles of reinforcement learning and optimal control theory. The main characteristics of the proposed controller are (i) simultaneous adjustment of both the insulin basal rate and the bolus dose, (ii) initialization based on clinical procedures, and (iii) real-time personalization. The effectiveness of the proposed algorithm in terms of glycemic control has been investigated in silico in adults, adolescents and children under open-loop and closed-loop approaches, using announced meals with uncertainties in the order of ±25% in the estimation of carbohydrates. The results show that glucose regulation is efficient in all three groups of patients, even with uncertainties in the level of carbohydrates in the meal. The percentages in the A+B zones of the Control Variability Grid Analysis (CVGA) were 100% for adults, and 93% for both adolescents and children. The AC based controller seems to be a promising approach for the automatic adjustment of insulin infusion in order to improve glycemic control. After optimization of the algorithm, the controller will be tested in a clinical trial.
Collapse
Affiliation(s)
- Elena Daskalaki
- ARTORG Center for Biomedical Engineering Research, Diabetes Technology Research Group, University of Bern, Murtenstrasse 50, 3010 Bern, Switzerland
| | | | | |
Collapse
|
48
|
Garcia-Gabin W, Jacobsen EW. Multilevel model of type 1 diabetes mellitus patients for model-based glucose controllers. J Diabetes Sci Technol 2013; 7:193-205. [PMID: 23439178 PMCID: PMC3692234 DOI: 10.1177/193229681300700125] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Glucose homeostasis is the result of complex interactions across different biological levels. This multilevel characteristic should be considered when analyzing and designing closed-loop glucose control algorithms. Classic control schemes use only a pharmacokinetic-pharmacodynamic (PKPD) perspective to describe the gluco-regulatory system. METHODS A multilevel model combining a PKPD model with an insulin signaling model is proposed for patients with type 1 diabetes mellitus T1DM (T1DM). The PKPD Dalla Man model for T1DM is expanded to include an intracellular level involving insulin signaling to control glucose uptake through glucose transporter type 4 (GLUT4) translocation. A model-based controller is then designed and used as an example to illustrate the feasibility of the proposal. RESULTS Two significant results were obtained for the controller explicitly utilizing multilevel information. No hypo-glycemic events were registered and an excellent performance for interpatient variability was achieved. Controller performance was evaluated using two indexes. The glucose was kept inside the range (70-180) mg/dl more than 99% of the time, and the intrapatient variability measured using control variability grid analysis was solid with 90% of the population inside the target zone. CONCLUSIONS Multilevel models open new possibilities for designing glucose control algorithms. They allow controllers to take into account variables that have a strong influence on glucose homeostasis. A model-based controller was used for demonstrating how improved knowledge of the multilevel nature of diabetes increases the robustness and performance of glucose control algorithms. Using the proposed multi-level approach, a reduction of the hypoglycemic risk and robust behaviour for intrapatient variability was demonstrated.
Collapse
Affiliation(s)
- Winston Garcia-Gabin
- Automatic Control Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden.
| | | |
Collapse
|
49
|
Bequette BW. Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas. ANNUAL REVIEWS IN CONTROL 2012; 36:255-266. [PMID: 23175620 PMCID: PMC3501007 DOI: 10.1016/j.arcontrol.2012.09.007] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Pursuit of a closed-loop artificial pancreas that automatically controls the blood glucose of individuals with type 1 diabetes has intensified during the past six years. Here we discuss the recent progress and challenges in the major steps towards a closed-loop system. Continuous insulin infusion pumps have been widely available for over two decades, but "smart pump" technology has made the devices easier to use and more powerful. Continuous glucose monitoring (CGM) technology has improved and the devices are more widely available. A number of approaches are currently under study for fully closed-loop systems; most manipulate only insulin, while others manipulate insulin and glucagon. Algorithms include on-off (for prevention of overnight hypoglycemia), proportional-integral-derivative (PID), model predictive control (MPC) and fuzzy logic based learning control. Meals cause a major "disturbance" to blood glucose, and we discuss techniques that our group has developed to predict when a meal is likely to be consumed and its effect. We further examine both physiology and device-related challenges, including insulin infusion set failure and sensor signal attenuation. Finally, we discuss the next steps required to make a closed-loop artificial pancreas a commercial reality.
Collapse
|
50
|
Li T, Evans AT, Chiravuri S, Gianchandani RY, Gianchandani YB. Compact, power-efficient architectures using microvalves and microsensors, for intrathecal, insulin, and other drug delivery systems. Adv Drug Deliv Rev 2012; 64:1639-49. [PMID: 22580183 DOI: 10.1016/j.addr.2012.05.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Revised: 05/01/2012] [Accepted: 05/03/2012] [Indexed: 12/25/2022]
Abstract
This paper describes a valve-regulated architecture, for intrathecal, insulin and other drug delivery systems, that offers high performance and volume efficiency through the use of micromachined components. Multi-drug protocols can be accommodated by using a valve manifold to modulate and mix drug flows from individual reservoirs. A piezoelectrically-actuated silicon microvalve with embedded pressure sensors is used to regulate dosing by throttling flow from a mechanically-pressurized reservoir. A preliminary prototype system is demonstrated with two reservoirs, pressure sensors, and a control circuit board within a 130cm(3) metal casing. Different control modes of the programmable system have been evaluated to mimic clinical applications. Bolus and continuous flow deliveries have been demonstrated. A wide range of delivery rates can be achieved by adjusting the parameters of the manifold valves or reservoir springs. The capability to compensate for changes in delivery pressure has been experimentally verified. The pressure profiles can also be used to detect catheter occlusions and disconnects. The benefits of this architecture compared with alternative options are reviewed.
Collapse
|